Pfizer Canada Defeats Neupogen Patent Claims On Obviousness
Company Now Holds NOC For Nivestym Filgrastim Biosimilar
With a biosimilar to Amgen’s Neupogen already on the market in the US, Pfizer has challenged key claims of Amgen’s Canadian drug substance patent, in an attempt to clear a path to market for its Nivestym biosimilar.
